MicroRNA-103 promotes tumor growth and metastasis in colorectal cancer by directly targeting LATS2

Zheng,Yong‑Bin; Xiao,Kuang; Xiao,Gao‑Chun; Tong,Shi‑Lun; Ding,Yu; Wang,Qiu‑Shuang; Li,Sheng‑Bo; Hao,Zhi‑Nan

doi:10.3892/ol.2016.4814

MicroRNA-103 promotes tumor growth and metastasis in colorectal cancer by directly targeting LATS2

Authors:
- Yong‑Bin Zheng
- Kuang Xiao
- Gao‑Chun Xiao
- Shi‑Lun Tong
- Yu Ding
- Qiu‑Shuang Wang
- Sheng‑Bo Li
- Zhi‑Nan Hao
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: July 5, 2016 https://doi.org/10.3892/ol.2016.4814
Pages: 2194-2200

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) has become the third most common cancer worldwide and leads to a high mortality rate. Although colorectal cancer has been studied widely, the underlying molecular mechanism remains unclear. Increasing evidence shows that the abnormal expression of microRNAs (miRNAs) is involved in tumorigenesis. Previous studies have reported that miRNA-103 (miR-103) is dysregulated in CRC; however, the expression, function and mechanism of miR-103 in CRC are not well known. The present study showed that miR‑103 was overexpressed in the primary tumor tissues of patients with CRC and was significantly associated with a more aggressive phenotype of CRC in patients. Survival rate analysis demonstrated that CRC patients with high miR‑103 expression had a poorer overall survival compared with CRC patients with low miR‑103 expression. In CRC cell lines, miR‑103 inhibition significantly decreased the proliferation, invasion and migration of the cells in vitro. Furthermore, miR‑103 repressed large tumor suppressor kinase 2 (LATS2) expression by directly binding to the LATS2-3'-untranslated region, and an inverse correlation was identified between the expression of miR‑103 and LATS2 messenger RNA in primary CRC tissues. In addition, the restoration of LATS2 led to suppressed proliferation, invasion and migration of CRC cells. In vivo, miR‑103 promotes tumor growth in nude mice. In summary, miR‑103 performs a critical role in the promotion of the invasive and metastatic capacities of CRC, possibly by directly targeting LATS2. This miRNA may be involved in the development and progression of CRC.

View Figures

View References

1	Talbot R and Kirkham S: Colorectal cancer. Lancet. 376:3302010. View Article : Google Scholar : PubMed/NCBI
2	Fujita T: Colorectal cancer. Lancet. 376:331–332. 2010. View Article : Google Scholar : PubMed/NCBI
3	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
4	Visone R and Croce CM: MiRNAs and cancer. Am J Pathol. 174:1131–1138. 2009. View Article : Google Scholar : PubMed/NCBI
5	Lujambio A and Lowe SW: The microcosmos of cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
6	Croce CM: miRNAs in the spotlight: Understanding cancer gene dependency. Nat Med. 17:935–936. 2011. View Article : Google Scholar : PubMed/NCBI
7	Bao Y, Chen Z, Guo Y, Feng Y, Li Z, Han W, Wang J, Zhao W, Jiao Y, Li K, et al: Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and Smad2. PLoS One. 9:e1059912014. View Article : Google Scholar : PubMed/NCBI
8	Wang Z, Sun X, Wang Y, Liu X, Xuan Y and Hu S: Association between miR-27a genetic variants and susceptibility to colorectal cancer. Diagn Pathol. 9:1462014. View Article : Google Scholar : PubMed/NCBI
9	Yuan W, Sui C, Liu Q, Tang W, An H and Ma J: Up-regulation of microRNA-145 associates with lymph node metastasis in colorectal cancer. PLoS One. 9:e1020172014. View Article : Google Scholar : PubMed/NCBI
10	Feng Y, Zhu J, Ou C, Deng Z, Chen M, Huang W and Li L: MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1. Br J Cancer. 110:2300–2309. 2014. View Article : Google Scholar : PubMed/NCBI
11	Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, et al: APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest. 121:4526–4536. 2011. View Article : Google Scholar : PubMed/NCBI
12	Yau TO, Wu CW, Dong Y, Tang CM, Ng SS, Chan FK, Sung JJ and Yu J: microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer. 111:1765–1771. 2014. View Article : Google Scholar : PubMed/NCBI
13	Ress AL, Stiegelbauer V, Winter E, Schwarzenbacher D, Kiesslich T, Lax S, Jahn S, Deutsch A, Bauernhofer T, Ling H, et al: MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients. Mol Carcinog. 54:1442–1450. 2015. View Article : Google Scholar : PubMed/NCBI
14	Wang Y, Tang Q, Li M, Jiang S and Wang X: MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA. Biochem Biophys Res Commun. 444:199–204. 2014. View Article : Google Scholar : PubMed/NCBI
15	Geng L, Sun B, Gao B, Wang Z, Quan C, Wei F and Fang XD: MicroRNA-103 promotes colorectal cancer by targeting tumor suppressor DICER and PTEN. Int J Mol Sci. 15:8458–8472. 2014. View Article : Google Scholar : PubMed/NCBI
16	Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J, Wang WC, Lin FM, Chen Z, Huang HD, et al: miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res. 72:3631–3641. 2012. View Article : Google Scholar : PubMed/NCBI
17	Hong Z, Feng Z, Sai Z and Tao S: PER3, a novel target of miR-103, plays a suppressive role in colorectal cancer in vitro. BMB Rep. 47:500–505. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zhao B, Lei QY and Guan KL: The Hippo-YAP pathway: New connections between regulation of organ size and cancer. Curr Opin Cell Biol. 20:638–646. 2008. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
21	Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A and Zavolan M: MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 474:649–653. 2011. View Article : Google Scholar : PubMed/NCBI
22	Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ and Richards AM: Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail. 15:1138–1147. 2013. View Article : Google Scholar : PubMed/NCBI
23	Yu D, Zhou H, Xun Q, Xu X, Ling J and Hu Y: microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. Oncol Lett. 3:1221–1226. 2012.PubMed/NCBI
24	Pan D: The hippo signaling pathway in development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
25	Takahashi Y, Miyoshi Y, Morimoto K, Taguchi T, Tamaki Y and Noguchi S: Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers. J Cancer Res Clin Oncol. 133:501–509. 2007. View Article : Google Scholar : PubMed/NCBI
26	Strazisar M, Mlakar V and Glavac D: LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma. Lung Cancer. 64:257–262. 2009. View Article : Google Scholar : PubMed/NCBI
27	Yang X, Yu J, Yin J, Xiang Q, Tang H and Lei X: MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2. Pharmazie. 67:645–651. 2012.PubMed/NCBI
28	Li J, Chen X, Ding X, Cheng Y, Zhao B, Al Hezaimik, Hakem R, Guan KL, Wang CY and Lai ZC: LATS2 suppresses oncogenic Wnt signaling by disrupting beta-catenin/BCL9 interaction. Cell Rep. 5:1650–1663. 2013. View Article : Google Scholar : PubMed/NCBI